Table 3. Tumour targeting.
|
bsMAb dose/interval/peptide dose |
||||
|---|---|---|---|---|
| 75 mg/5 days/100 μg | 75 mg/1 day/100 μg | 150 mg/1 day/100 μg | 75 mg/1 day/25 μg | |
| Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | |
|
Activity concentration (%ID kg−1, mean (range)) | ||||
| Tumour |
1.4 (0.8–2.0) |
4.4 (2.7–5.7) |
5.9 (3.1–10.4) |
9.4 (2.2–23.6) |
| Normal tissue |
0.068 (0.042–0.093) |
0.18 (0.12–0.24) |
0.19 (0.08–0.31) |
0.21 (0.10–0.28) |
| Tumour-to-normal tissue ratio (mean (range)) | 20 (17–22) | 24 (20–29) | 32 (22–43) | 40 (21–84) |
Abbreviation: ID=injected dose.